Gacos JAB-21822 combined with cetuximab completed administration of the first case of colorectal cancer

Gacos Pharmaceuticals (1167.HK) KRAS G12C inhibitor JAB-21822 was administered to the first patient who recently completed a combined drug trial with tuximab at Beijing Cancer Hospital.

JAB-21822 is used in combination with cetuximab to treat advanced colorectal cancer with KRAS G12C mutation. Colorectal cancer is the second most common tumor in China. The number of new cases per year is about 550,000. Of these, about 3% of colorectal cancer patients have KRAS G12C mutations. Patients carrying the KRAS G12C mutation gene are not sensitive to existing standardized treatments or targeted treatments. The disease progresses rapidly, the survival period is short, and there is a high level of unmet clinical treatment needs.

JAB-21822 is the first KRAS G12C inhibitor in China to be treated in combination with cetuximab. Professor Shen Lin, associate director of Peking University Cancer Hospital and director of the Department of Gastroenterological Oncology, acted as the main researcher in this combined drug trial. Professor Shen Lin said, “Judging from the global development of KRAS G12C inhibitors, both single drug and combination drug studies have shown initial therapeutic effects in colorectal cancer patients. Gacos's JAB-21822 has progressed rapidly since the application for combined cetuximab was submitted to the CDE in August 2021, and is currently the fastest progressing research project among similar combination drugs in China. We hope to work closely with the Gacos team to be patient-centered, and hope this drug will soon become a new treatment option for advanced colorectal cancer patients in China.”

Dr. Wang Yinxiang, Chairman and CEO of Gacos, said, “JAB-21822 has the potential to become the best in its class due to its high activity and dosage advantages, which is expected to improve patients' adherence to medication and quality of life.”

Currently, JAB-21822 is simultaneously carrying out single drug and combined drug clinical studies in China and the US. These include treating STK11 co-mutated non-small cell lung cancer as a first-line therapy; co-administration with the self-developed SHP2 inhibitor JAB-3312 to solve KRAS resistance; and co-administration with PD-1 monoclonal antibodies to improve PD-1 response rate.

KRAS G12C is the first Gacos project to enter clinical trials on the RAS signaling pathway. Furthermore, projects on the RAS pathway, such as KRAS G12D and KRAS G12V, are in the pre-clinical development stage.

About Gacos

Gacos (1167.HK) is committed to providing patients with breakthrough treatment solutions. The company's mission is to be an innovator in biomedicine and provide effective innovative treatments for patients around the world. The company's vision is to work hand in hand with partners to become a globally recognized leader in drug development. The company's laboratories are located in Beijing, China, Shanghai, and Massachusetts, USA. The experimental platform has technology to develop allosteric inhibitors of protein phosphatase, KRAS, and other transcription factors.

Forward-looking statements

The information published in this press release may include certain forward-looking statements. These statements are inherently risky and uncertain. When using “anticipate”, “believe”, “anticipate”, “expect”, “intention” and other similar terms, the purpose is to indicate that anything relating to the Company is a forward-looking statement. The Company is under no obligation to update these predictive statements on an ongoing basis.

These forward-looking statements are based on the Company's management's current views, assumptions, expectations, estimates, predictions, and understandings of future matters at the time of making the statements. These statements are not a guarantee of future development and are subject to risk, uncertainty and other factors. Some are beyond our control and difficult to predict. Therefore, due to future changes and developments in our business, competitive environment, and China's political, economic, legal and social conditions, actual results may differ significantly from the information contained in the forward-looking statements.

The Company, its directors and employee agents do not assume (a) any obligation to correct or update the forward-looking statements contained on this website; and (b) if any forward-looking statement is unfulfilled or becomes incorrect.

31K Views